ID26091A - Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin - Google Patents

Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin

Info

Publication number
ID26091A
ID26091A IDW20001882A ID20001882A ID26091A ID 26091 A ID26091 A ID 26091A ID W20001882 A IDW20001882 A ID W20001882A ID 20001882 A ID20001882 A ID 20001882A ID 26091 A ID26091 A ID 26091A
Authority
ID
Indonesia
Prior art keywords
derivates
campototesin
antrasicline
composition containing
synergistic combination
Prior art date
Application number
IDW20001882A
Other languages
English (en)
Indonesian (id)
Inventor
Geroni Cristina
Ripamonti Marina
Caruso Michele
Suarato Antonino
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ID26091A publication Critical patent/ID26091A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20001882A 1998-03-24 1999-03-19 Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin ID26091A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition

Publications (1)

Publication Number Publication Date
ID26091A true ID26091A (id) 2000-11-23

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001882A ID26091A (id) 1998-03-24 1999-03-19 Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin

Country Status (29)

Country Link
US (1) US6403563B1 (cs)
EP (1) EP1067941B1 (cs)
JP (1) JP2002507571A (cs)
KR (1) KR20010034619A (cs)
CN (2) CN1528334A (cs)
AR (1) AR018166A1 (cs)
AT (1) ATE271388T1 (cs)
AU (1) AU758191B2 (cs)
BR (1) BR9908391A (cs)
CA (1) CA2324610A1 (cs)
CZ (1) CZ295368B6 (cs)
DE (1) DE69918819T2 (cs)
DK (1) DK1067941T3 (cs)
EA (1) EA003134B1 (cs)
ES (1) ES2226366T3 (cs)
GB (1) GB9806324D0 (cs)
HU (1) HUP0101615A3 (cs)
ID (1) ID26091A (cs)
IL (1) IL138035A0 (cs)
MY (1) MY133016A (cs)
NO (1) NO20004703D0 (cs)
NZ (1) NZ507570A (cs)
PL (1) PL343098A1 (cs)
PT (1) PT1067941E (cs)
SI (1) SI1067941T1 (cs)
TW (1) TW576740B (cs)
UA (1) UA63000C2 (cs)
WO (1) WO1999048503A1 (cs)
ZA (1) ZA992255B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP4462120A3 (en) 2012-02-23 2025-01-08 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
US11091808B2 (en) 2012-06-07 2021-08-17 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
PT2981624T (pt) 2013-04-05 2020-03-23 Myriad Genetics Inc Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
MX370462B (es) 2014-03-07 2019-12-13 Secure Natural Resources Llc Oxido de cerio (iv) con propiedades de remocion de arsenico excepcionales.
ES3039109T3 (en) 2014-08-15 2025-10-17 Myriad Genetics Inc Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
EA200000978A1 (ru) 2001-02-26
UA63000C2 (en) 2004-01-15
EP1067941B1 (en) 2004-07-21
EP1067941A1 (en) 2001-01-17
SI1067941T1 (en) 2005-02-28
IL138035A0 (en) 2001-10-31
MY133016A (en) 2007-10-31
HUP0101615A2 (hu) 2001-10-28
US6403563B1 (en) 2002-06-11
DK1067941T3 (da) 2004-11-29
NZ507570A (en) 2003-01-31
EA003134B1 (ru) 2003-02-27
GB9806324D0 (en) 1998-05-20
CN1528334A (zh) 2004-09-15
PL343098A1 (en) 2001-07-30
AR018166A1 (es) 2001-10-31
CN1294516A (zh) 2001-05-09
JP2002507571A (ja) 2002-03-12
TW576740B (en) 2004-02-21
NO20004703L (no) 2000-09-20
KR20010034619A (ko) 2001-04-25
NO20004703D0 (no) 2000-09-20
CN1150002C (zh) 2004-05-19
DE69918819D1 (de) 2004-08-26
DE69918819T2 (de) 2005-08-18
ATE271388T1 (de) 2004-08-15
WO1999048503A1 (en) 1999-09-30
CZ295368B6 (cs) 2005-07-13
CZ20003493A3 (cs) 2001-02-14
CA2324610A1 (en) 1999-09-30
PT1067941E (pt) 2004-12-31
ZA992255B (en) 1999-10-05
BR9908391A (pt) 2000-10-31
ES2226366T3 (es) 2005-03-16
HUP0101615A3 (en) 2002-12-28
AU758191B2 (en) 2003-03-20
AU3331499A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
ID26091A (id) Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin
PT1049467E (pt) Composicoes de celecoxib
PT2270172E (pt) Composições de neisseria de combinação
DK2301541T3 (da) Antibiotiske sammensætninger til behandling af øjet
PT1165069E (pt) Composicao sinergistica antitumoral
DE60234212D1 (de) Farbeffekt zusammensetzungen
DE60016727D1 (de) Mehrkomponentenbleichmittelzusammensetzungen
PL330949A1 (en) Antibacterial compositions
GB9924268D0 (en) Compositions
PL373562A1 (en) Color compositions
HUP0004905A3 (en) Synergistic biocide composition
EP1320385A4 (en) COMBINATION COMPOSITIONS
GB9828861D0 (en) Compositions
HUP0104413A3 (en) Topical compositions comprising ascomycins
HUP0102520A3 (en) Sweetener compositions
GB0212605D0 (en) Stabilising composition
EP1103650A4 (en) PLASTICISERS COMPOSITION
GB2339693B (en) Anti-mollusc compositions
GB9827291D0 (en) Compositions
GB0108133D0 (en) Substituted polycyclic compounds
GB2336535B (en) Compositions
GB9809347D0 (en) Compositions
GB9913511D0 (en) Compositions stabilized by dioxopiperazinyl derivatives
GB9827690D0 (en) Compositions
GB0121162D0 (en) Gearing arrangement